Follow Us
© 2026 Arizent. All rights reserved.
Hundreds of biotech and pharmaceutical industry executives condemned a ruling by a federal judge in Texas to suspend the U.S. government’s decades-old approval of a key drug used in medication abortion.
In a joint open letter, executives including Pfizer CEO Albert Bourla said that Friday’s ruling by U.S. District Judge Matthew Kacsmaryk undermined the U.S. regulators authority and called for the “reversal of this decision to disregard science.”
For reprint and licensing requests for this article, click here.
As the scope of gene therapy grows, understanding their impact and cost can help organizations decide how to cover them through their healthcare plans.
A look at traditional PBMs and pass-through models, potential savings areas, developments and partnering with the right consultant.
The Department of Labor issued a safe harbor rule protecting benefit leaders as they navigate the added risk to retirement planning.
You Powered Symposium earmarks $50,000 between Radial's treatment for a wide range of brain disorders and Hibiscus Health's cardiometabolic risk screening.
High-priced treatments, administered in expensive facilities, are becoming one of the largest cost drivers within prescription plans.
